Treats relapsing forms of multiple sclerosis (MS). Sold as Bafiertam. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Monomethyl Fumarate (sold as Bafiertam), first approved Apr 28, 2020, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Bafiertam | Part D | $15.5M | +88% | 275 |
| Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and SerologicMultiple Sclerosis · University Hospital, Montpellier | Not applicable | Recruiting | Jul 27, 2023 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSMultiple Sclerosis, Relapsing-Remitting · The Cleveland Clinic | Phase 4 | Active, not recruiting | May 24, 2018 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 28, 2020 | BafiertamNDA 210296 · New active ingredient | Banner Life Sciences | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA